Indapta Therapeutics

What Indapta Therapeutics does

Indapta Therapeutics is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company's proprietary platform is centered on FcRγ-deficient "g-NK" cells, a naturally occurring subset of NK cells derived from healthy donors that demonstrate increased cytokine secretion, higher cytolytic enzyme levels, a more favorable metabolic profile, increased persistence, and markedly higher antibody-dependent cellular cytotoxicity (ADCC) compared to conventional NK cells. Indapta has developed a proprietary expansion process that yields a potent product without the need for artificial genetic engineering, positioning the platform as an off-the-shelf alternative to autologous CAR T-cell therapies. Its lead clinical candidate, IDP-023, is being evaluated in Phase 1/2 trials in relapsed/refractory non-Hodgkin's lymphoma and multiple myeloma (in combination with FDA-approved monoclonal antibodies rituximab, daratumumab, and isatuximab), with a Phase 1 trial in progressive multiple sclerosis also underway.

The company is headquartered in Houston, Texas with research and development operations in Seattle, Washington. Indapta operates through clinical trial collaborations with pharmaceutical companies and biotech partners, including a clinical study collaboration with Sanofi for its multiple myeloma program and a strategic manufacturing partnership with Lonza for GMP production. The company is pre-revenue and has raised approximately $128 million cumulatively across a $50 million Series A in February 2022 (co-led by RA Capital Management, Vertex Ventures HC, and Leaps by Bayer), a $22.5 million round in December 2024, a $4.5 million CPRIT grant in May 2024, and an approximately $50.8 million capital raise disclosed via SEC Form D in October 2025. The company has received FDA Fast Track Designation for IDP-023 in non-Hodgkin's lymphoma and myeloma, FDA IND clearance for the multiple sclerosis program, and is led by CEO Mark W. Frohlich, M.D., who was appointed in February 2022.

The business model is typical of a clinical-stage biotech: the company is pre-revenue with no commercial product, no public pricing, and no current licensing revenue. Future revenue is expected to derive from commercialization of IDP-023 and pipeline products for cancer and autoimmune diseases upon regulatory approval, supplemented by potential licensing and partnership deals with pharmaceutical companies for clinical development and co-commercialization. Target end customers are patients with relapsed/refractory hematologic malignancies and progressive autoimmune diseases treated through approved therapies and clinical trial sites, with healthcare providers and clinical trial investigators as intermediate channels.

Name

Indapta Therapeutics

Legal name

Indapta Therapeutics Inc.

Website

https://indapta.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Indapta Therapeutics is a clinical-stage biotechnology company developing allogeneic FcRγ-deficient natural killer (G-NK) cell therapies, with lead candidate IDP-023 in Phase 1/2 trials for relapsed/refractory non-Hodgkin's lymphoma, multiple myeloma, and progressive multiple sclerosis. The company serves cancer and autoimmune disease patients via an off-the-shelf platform partnered with Lonza and Sanofi.

Ownership category

akta.pro rank

Product category

Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

NK Cell Therapies (HLAAABAD)

akta.pro secondary industries

Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Allogeneic cell therapy
• Natural killer cells
• Cancer immunotherapy
• Autoimmune disease therapy
• Cell therapy platform

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Cell Therapy Commercialization: Pre-revenue biotech company developing allogeneic NK cell therapies. Revenue will be generated from commercialization of IDP-023 and future pipeline products for cancer and autoimmune diseases once clinical trials are completed and regulatory approvals are obtained.
2. Partnership and Licensing Revenue: Potential licensing and partnership deals with pharmaceutical companies for clinical development, co-commercialization, or regional partnerships. The Sanofi clinical study collaboration represents an early example of this model.
3. Grant Funding: Non-dilutive funding from government and foundation grants, such as the $4.5 million CPRIT grant for clinical development.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Indapta Therapeutics develops a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy platform for the treatment of cancer and autoimmune diseases. The company's lead clinical candidate IDP-023 is being evaluated in Phase 1/2 clinical trials for relapsed/refractory non-Hodgkin's lymphoma, multiple myeloma, and progressive multiple sclerosis, used alone or in combination with FDA-approved monoclonal antibodies.

Product overview

Indapta Therapeutics is developing a universal, allogeneic NK cell therapy platform based on naturally occurring g-NK cells (FcRγ-deficient natural killer cells) that have undergone epigenetic changes making them particularly potent at killing cancer cells and autoreactive T and B cells. The lead clinical candidate is IDP-023, which is being evaluated in Phase 1/2 trials for relapsed/refractory non-Hodgkin's lymphoma, multiple myeloma, and progressive multiple sclerosis, either as monotherapy or in combination with FDA-approved monoclonal antibodies. The platform uses a proprietary process to expand g-NK cells without artificial genetic engineering, providing an off-the-shelf alternative to CAR T-cell treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• G-NK Cell Therapy Platform

Quantifiable outcome

• Significant tumor reduction observed in Phase 1/2 trial with IDP-023 alone and in combination with isatuximab in relapsed/refractory multiple myeloma patients
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• SanoficoreStrategic or Co-development Partner · 6 December 2024Clinical study collaboration announced December 2024 for the multiple myeloma program. The collaboration involves studying Indapta's IDP-023 g-NK cell therapy in combination with Sanofi's therapeutic agents for multiple myeloma treatment.
• LonzacoreStrategic or Co-development Partner · 10 January 2020Strategic partnership announced in January 2020 to advance a next-generation, off-the-shelf, allogeneic immuno-oncology therapy. Lonza provides contract manufacturing services for Indapta's G-NK cell therapy platform, leveraging their cell therapy manufacturing expertise and facilities.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Nkarta Therapeutics: Clinical-stage biotech developing allogeneic, off-the-shelf NK cell therapies (NKX019, NKX101) for hematologic malignancies and autoimmune diseases. Directly comparable to Indapta on allogeneic NK platform, target indications (NHL, MM), and partnership-driven commercialization model.
• Fate Therapeutics: Clinical-stage biotech developing iPSC-derived, off-the-shelf NK and T-cell therapies (e.g., FT516, FT825) for cancer and autoimmune indications. Direct competitor in the allogeneic NK space with a broader iPSC-based platform; comparable on manufacturing scalability strategy.
• Century Therapeutics: Clinical-stage biotech developing iPSC-derived allogeneic NK and T-cell therapies for hematologic cancers and autoimmune diseases. Competes with Indapta in allogeneic NK cell therapy and shares a similar platform-plus-pipeline business model.
• Shoreline Biosciences: Clinical-stage biotech developing iPSC-derived NK cell therapies for cancer, partnered with Kite/Gilead and BeiGene. Direct comparable to Indapta on NK cell therapy platform, partnership-driven business model, and oncology focus.
• ImmunityBio: Commercial-stage biotech developing NK-92-based cell therapies including the approved Anktiva (N-803 + NK-92) for bladder cancer. Comparable to Indapta on NK cell modality and oncology indications, with the additional signal of an approved NK product in the same class.

Emerging players

• Adicet Bio: Clinical-stage biotech developing off-the-shelf gamma delta T-cell therapies (related innate-like immune cell family) for hematologic malignancies and autoimmune diseases. Comparable to Indapta on allogeneic platform, off-the-shelf delivery, and indication overlap.
• ONK Therapeutics: Pre-clinical/early-clinical biotech developing engineered NK cell therapies (including CAR-NK and affinity-tuned NK) for cancer. Comparable to Indapta on NK modality and hematologic/oncology focus, though at an earlier stage of development.
• Kyverna Therapeutics: Clinical-stage biotech developing cell therapies (CAR-T) for autoimmune diseases including multiple sclerosis and lupus. Comparable to Indapta on the autoimmune cell therapy expansion thesis, particularly for the progressive MS indication.
• Cabaletta Bio: Clinical-stage biotech developing CAR-T cell therapies for autoimmune diseases (e.g., lupus, MS). Comparable to Indapta's autoimmune expansion strategy and provides a benchmark for autoimmune cell therapy clinical and commercial development.

Broad incumbents

• Allogene Therapeutics: Clinical-stage biotech developing allogeneic CAR-T cell therapies across multiple hematologic cancers. While focused on CAR-T rather than NK, it is a comparable allogeneic, off-the-shelf cell therapy competitor with broader pipeline scale and capital base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds8 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Indapta Therapeutics